VERICEL CORPORATION Debt Securities, Available-for-sale, Amortized Cost
VERICEL CORPORATION (VCEL) had Debt Securities, Available-for-sale, Amortized Cost of $102.44 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $102.44M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $101.50M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $98.53M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $84.38M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $102.44M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $101.50M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $98.53M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $84.38M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $83.57M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $82.62M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $81.57M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $80.59M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $78.61M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $77.39M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $65.85M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $65.56M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $76.42M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $77.98M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $89.41M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $68.61M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $69.21M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $68.30M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $60.91M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $64.00M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $70.09M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $70.07M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $66.27M 10-K · filed 2022-02-24 | $69.97M 10-K · filed 2021-02-24 |
| 2020-09-30 | $70.02M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $69.93M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $69.70M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $57.44M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $57.16M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $56.84M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $75.94M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $75.52M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $75.18M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |